Psychoactive Substances Act 2013

Last updated

Psychoactive Substances Act
Coat of arms of New Zealand.svg
New Zealand Parliament
Royal assent 17 July 2013
Commenced18 July 2013
Legislative history
Bill citation Government Bill 100—1
Introduced by Peter Dunne
First reading 9 April 2013
Status: Current legislation

The Psychoactive Substances Act 2013 is a law in New Zealand. The purpose of the Act is to regulate the availability of psychoactive substances in New Zealand to protect the health of, and minimise harm to, individuals who use psychoactive substances. [1] The law seeks to make manufacturers test and prove their products are low-risk before they can be sold. [2] [3] [4]

Testing is expected to cost manufacturers $1 to 2 million dollars. There is also an $180,000 application fee. [5] A later addition to the law, Section 4(f), specified that "animals must not be used in trials for the purposes of assessing whether a psychoactive product should be approved." This may mean that, in practice, approval will be difficult or impossible. [6] So far, no manufacturing licenses have been applied for. [7]

The Act was brought in as a reaction to widespread concerns [8] over the 2005 deregulation, or decriminalisation, of selling psychoactive substances in New Zealand with the introduction of section 62 in the Misuse of Drugs Amendment Act 2005 and the Misuse of Drugs (Restricted Substances) Regulations 2008. [9] These laws made psychoactive substances such as party pills and legal highs available in New Zealand in a relatively new experimental market aimed at decriminalising the production and sale of recreational drugs. [10]

Related Research Articles

<span class="mw-page-title-main">Prohibition of drugs</span> History, effects and enforcement of the prohibition of drugs

The prohibition of drugs through sumptuary legislation or religious law is a common means of attempting to prevent the recreational use of certain intoxicating substances.

<span class="mw-page-title-main">Misuse of Drugs Act 1971</span> United Kingdom legislation

The Misuse of Drugs Act 1971 is an Act of the Parliament of the United Kingdom. It represents action in line with treaty commitments under the Single Convention on Narcotic Drugs, the Convention on Psychotropic Substances, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.

A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids. Some of these were originally synthesized by academic or industrial researchers in an effort to discover more potent derivatives with fewer side effects and shorter duration and were later co-opted for recreational use. Other designer drugs were prepared for the first time in clandestine laboratories. Because the efficacy and safety of these substances have not been thoroughly evaluated in animal and human trials, the use of some of these drugs may result in unexpected side effects.

<span class="mw-page-title-main">Regulation of therapeutic goods</span> Legal management of drugs and restricted substances

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

<span class="mw-page-title-main">Benzylpiperazine</span> Recreational drug

Benzylpiperazine (BZP) is a recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. Adverse effects have been reported following its use including acute psychosis, renal toxicity and seizures. Deaths from piperazine derivatives are extremely rare, but there has been at least one death apparently due to BZP alone. Its sale is banned in several countries, including Australia, Canada, New Zealand, the United States, the Republic of Ireland, the United Kingdom, Bulgaria, Romania and other parts of Europe.

<span class="mw-page-title-main">Misuse of Drugs Act 1975</span> Act of Parliament in New Zealand

The Misuse of Drugs Act 1975 is a New Zealand drug control law that classifies drugs into three classes, or schedules, purportedly based on their projected risk of serious harm. However, in reality, classification of drugs outside of passing laws, where the restriction has no legal power, is performed by the governor-general in conjunction with the Minister of Health, neither of whom is actually bound by law to obey this restriction.

<span class="mw-page-title-main">Methylone</span> Group of stereoisomers

Methylone is an empathogen and stimulant psychoactive drug. It is a member of the substituted amphetamine, substituted cathinone and substituted methylenedioxyphenethylamine classes.

<span class="mw-page-title-main">Party pills</span> Type of recreational drugs

Party pills, also known as "herbal highs", "pep pills" "dance pills" and "natural power", is a colloquialism for a type of recreational drug whose main ingredient was originally benzylpiperazine (BZP), but has expanded to a wide range of compounds with a variety of effects. BZP is banned in a few countries, including the USA, Republic of Ireland, Australia and New Zealand, but is available on a more or less restricted basis in many jurisdictions. A range of other piperazine derivatives have also been sold as ingredients in party pills, and many of these branded "proprietary blends" have subsequently been sold in countries around the world.

<span class="mw-page-title-main">Phenazepam</span> Chemical compound

Phenazepam is a benzodiazepine drug, which was developed in the Soviet Union in 1975, and now produced in Russia and some CIS countries.

Salvia divinorum, a psychoactive plant, is legal in most countries. Exceptions, countries where there is some form of control, include Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Italy, Japan, South Korea, Norway, Poland, United Kingdom, Ukraine, Spain, Sweden, Armenia and 33 states and territories of the United States.

<span class="mw-page-title-main">Methylbenzylpiperazine</span> Chemical compound

Methylbenzylpiperazine is a stimulant drug which is a derivative of benzylpiperazine. MBZP has been sold as an ingredient in legal recreational drugs known as "party pills", initially in New Zealand and subsequently in other countries around the world.

<span class="mw-page-title-main">Cannabis in New Zealand</span> Use of cannabis in New Zealand

The use of cannabis in New Zealand is regulated by the Misuse of Drugs Act 1975, which makes unauthorised possession of any amount of cannabis a crime. Cannabis is the fourth-most widely used recreational drug in New Zealand, after caffeine, alcohol and tobacco, and the most widely used illicit drug. In 2001 a household survey revealed that 13.4% of New Zealanders aged 15–64 used cannabis. This ranked as the ninth-highest cannabis consumption level in the world.

<span class="mw-page-title-main">Synthetic cannabinoids</span> Designer drugs

Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic phytocannabinoids or synthetic endocannabinoids from which they are in many aspects distinct.

<span class="mw-page-title-main">6-APB</span> Psychoactive drug

6-APB is an empathogenic psychoactive compound of the substituted benzofuran and substituted phenethylamine classes. 6-APB and other compounds are sometimes informally called "Benzofury" in newspaper reports. It is similar in structure to MDA, but differs in that the 3,4-methylenedioxyphenyl ring system has been replaced with a benzofuran ring. 6-APB is also the unsaturated benzofuran derivative of 6-APDB. It may appear as a tan grainy powder. While the drug never became particularly popular, it briefly entered the rave and underground clubbing scene in the UK before its sale and import were banned. It falls under the category of research chemicals, sometimes called "legal highs." Because 6-APB and other substituted benzofurans have not been explicitly outlawed in some countries, they are often technically legal, contributing to their popularity.

<span class="mw-page-title-main">RCS-4</span> Chemical compound

RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole, is a synthetic cannabinoid drug sold under the names SR-19, BTM-4, or Eric-4, but originally, OBT-199.

Matt "Starboy" Bowden is a rock musician and activist from New Zealand. Previously known as the "Godfather of the legal highs industry", he is credited with creating non-lethal, non-addictive party pills as safer substitutes for methamphetamine addicts, and successfully lobbying in New Zealand for a quality control and regulatory system for psychoactive substances. He performs musically as Starboy and produces progressive rock music with elaborate theatrical stage shows, and produces short films, most notably Starboy Eternity.

A temporary class drug is a relatively new status for controlled drugs, which has been adopted in some jurisdictions, notably New Zealand and the United Kingdom, to attempt to bring newly synthesised designer drugs under legal control. The controlled drug legislation in these jurisdictions requires drug scheduling decisions to follow an evidence-based process, where the harms of the drug are assessed and reviewed so that an appropriate legal status can be assigned. Since many designer drugs sold in recent years have had little or no published research that could help inform such a decision, they have been widely sold as "legal highs", often for months, before sufficient evidence accumulates to justify placing them on the controlled drug schedules.

<span class="mw-page-title-main">Psychoactive Substances Act 2016</span> United Kingdom legislation

The Psychoactive Substances Act 2016 is an Act of the Parliament of the United Kingdom intended to restrict the production, sale and supply of a new class of psychoactive substances often referred to as "legal highs". The bill was given Royal Assent on 28 January 2016, and came into force on 26 May 2016 across the entire United Kingdom.

Drug checking or pill testing is a way to reduce the harm from drug consumption by allowing users to find out the content and purity of substances that they intend to consume. This enables users to make safer choices: to avoid more dangerous substances, to use smaller quantities, and to avoid dangerous combinations.

<span class="mw-page-title-main">Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018</span> Act of Parliament in New Zealand

The Misuse of Drugs Amendment Act 2018 is an Act of Parliament in New Zealand which amends the Misuse of Drugs Act 1975 to allow terminally-ill people to consume cannabis and to possess a cannabis utensil. The bill passed its third reading on 11 December 2018. It was supported by the centre-left Labour Party and its coalition partners New Zealand First and the Green parties but was opposed by the opposition centre-right National Party. The Act received royal assent on 17 December and came into force on 18 December 2018.

References

  1. "Psychoactive Substances Act 2013". New Zealand Legislation. 17 July 2013. Retrieved 2 December 2022.
  2. Easton, Mark (28 February 2013). "Kiwis on drugs: A blueprint for the future?". BBC. Retrieved 30 March 2013.
  3. "Force of habits: the end for global drug prohibition?". South China Morning Post Publishers Ltd. New Scientist. 22 March 2014. Retrieved 13 April 2014.
  4. "New Zealand a 'world leader' on party pills". New Zealand Herald. APN. 17 March 2013. Retrieved 30 March 2013.
  5. "Dairy drug sales to be banned within weeks". The New Zealand Herald. 25 May 2013. Retrieved 25 May 2013.
  6. "The twilight state of the Psychoactive Substances Act", November 2014, New Zealand Drug Foundation magazine "Matters of Substance"
  7. "Synthetic Cannabis 'Prevalent' - Ban hasn't fixed problem", Jul 9, 2016, Kyra Dawson, Rotorua Daily Post
  8. "Kronic ads on youth radio under fire", Nicholas Jones, Jun 28, 2011, NZ Herald
  9. "Misuse of Drugs (Restricted Substances) Regulations 2008". New Zealand Legislation. 6 October 2008. Retrieved 27 May 2013.
  10. "A Kronic desire for anonymity", 12/06/2011, stuff.co.nz